• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Blackstone Tactical Opportunities Fund - Fd L.P. claimed ownership of 25,156,993 units of Class A Common Stock

    8/30/21 4:31:21 PM ET
    $CMLF
    Business Services
    Finance
    Get the next $CMLF alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Blackstone Tactical Opportunities Fund - FD L.P.

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/22/2021
    3. Issuer Name and Ticker or Trading Symbol
    Sema4 Holdings Corp. [ SMFR ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Class A Common Stock 24,404,324 I See Footnotes(1)(5)(7)(10)(11)(12)
    Class A Common Stock 505,095 I See Footnotes(2)(6)(7)(10)(11)(12)
    Class A Common Stock 147,574 I See Footnotes(3)(5)(7)(10)(11)(12)
    Class A Common Stock 100,000 I See Footnotes(4)(6)(7)(10)(11)(12)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrants to purchase Class A Common Stock (right to buy) 09/05/2021 09/05/2027 Class A Common Stock 709,509 11.5 I See Footnotes(4)(6)(7)(10)(11)(12)
    Earnout Rights (8)(9) 07/22/2023 Class A Common Stock 2,750,264(8)(9) (8)(9) I See Footnotes(1)(5)(7)(10)(11)(12)
    Earnout Rights (8)(9) 07/22/2023 Class A Common Stock 56,922(8)(9) (8)(9) I See Footnotes(2)(6)(7)(10)(11)(12)
    Earnout Rights (8)(9) 07/22/2023 Class A Common Stock 16,632(8)(9) (8)(9) I See Footnotes(3)(5)(7)(10)(11)(12)
    1. Name and Address of Reporting Person*
    Blackstone Tactical Opportunities Fund - FD L.P.

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Blackstone Tactical Opportunities Associates III - NQ L.P.

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BTO DE GP - NQ L.L.C.

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Blackstone Holdings II L.P.

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Blackstone Aqua Master Sub-Fund, a sub-fund of Blackstone Global Master Fund ICAV

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Blackstone Alternative Solutions L.L.C.

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Blackstone Holdings I L.P.

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Blackstone Holdings I/II GP L.L.C.

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Blackstone Family Tactical Opportunities Investment Partnership III ESC L.P.

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BTO Side-by-Side GP L.L.C.

    (Last) (First) (Middle)
    C/O BLACKSTONE INC.
    345 PARK AVENUE

    (Street)
    NEW YORK NY 10154

    (City) (State) (Zip)
    Explanation of Responses:
    1. Reflects securities directly held by BTO Sema4 Holdings L.P. BTO Holdings Manager L.L.C. is the general partner of BTO Sema4 Holdings L.P. Blackstone Tactical Opportunities Associates L.L.C. is the managing member of BTO Holdings Manager L.L.C. BTOA L.L.C. is the sole member of Blackstone Tactical Opportunities Associates L.L.C.
    2. Reflects securities of the Issuer held directly by Blackstone Tactical Opportunities Fund - FD L.P. Blackstone Tactical Opportunities Associates III - NQ L.P. is the general partner of Blackstone Tactical Opportunities Fund - FD L.P. BTO DE GP - NQ L.L.C. is the general partner of Blackstone Tactical Opportunities Associates III - NQ L.P. Blackstone Holdings II L.P. is the managing member of BTO DE GP-NQ L.L.C.
    3. Reflects securities directly held by Blackstone Family Tactical Opportunistic Investment Partnership III ESC L.P. BTO Side-by-Side GP L.L.C. is the general partner of Blackstone Family Tactical Opportunistic Investment Partnership III ESC L.P.
    4. Reflects securities directly held by Blackstone Aqua Master Sub-Fund, a sub-fund of Blackstone Global Master Fund ICAV. Blackstone Alternative Solutions L.L.C. is the investment manager of Blackstone Aqua Master Sub-Fund. Blackstone Holdings I L.P. is the sole member of Blackstone Alternative Solutions L.L.C.
    5. Blackstone Holdings III L.P. is the managing member of BTOA L.L.C. and the sole member of BTO Side-by-Side GP L.L.C. Blackstone Holdings III GP L.P. is the general partner of Blackstone Holdings III L.P. Blackstone Holdings III GP Management L.L.C. is the general partner of Blackstone Holdings III GP L.P.
    6. Blackstone Holdings I/II GP L.L.C. is the general partner of each of Blackstone Holdings I L.P. and Blackstone Holdings II L.P.
    7. Blackstone Inc. is the sole member of each of Blackstone Holdings I/II GP L.L.C. and Blackstone Holdings III GP Management L.L.C. The sole holder of the Series II preferred stock of Blackstone Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.
    8. Reflects Earnout Rights acquired pursuant to the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), pursuant to the terms of an Agreement and Plan of Merger, dated February 9, 2021, (as amended, the "Merger Agreement"). The transactions contemplated by the Merger Agreement closed on July 22, 2021.
    9. Pursuant to earnout provisions in the Merger Agreement, the Reporting Persons are entitled to receive shares of Class A Common Stock if, from the closing of the transaction until the second anniversary thereof, the volume-weighted average price of the Class A Common Stock equals or exceeds certain thresholds. Of these Earnout Rights, one-third will be issued if the volume-weighted average price of the Class A Common Stock equals or exceeds $13.00 for any 20 trading days within any 30 trading day period, one-third will be issued if the volume-weighted average price of the Class A Common Stock equals or exceeds $15.00 for any 20 trading days within any 30 trading day period, and one-third will be issued if the volume-weighted average price of the Class A Common Stock equals or exceeds $18.00 for any 20 trading days within any 30 trading day period, in each case, subject to adjustment as provided in the Merger Agreement.
    10. Due to the limitations of the electronic filing system certain Reporting Persons are filing a separate Form 3.
    11. Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.
    12. Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
    Remarks:
    BLACKSTONE TACTICAL OPPORTUNITIES FUND - FD L.P. , By: Blackstone Tactical Opportunities Associates III - NQ L.P., GP, By: BTO DE GP - NQ L.L.C., GP, By: Blackstone Holdings II L.P., MM, By: Blackstone Holdings I/II GP L.L.C., GP, By: /s/ Tabea Hsi, SMD 08/30/2021
    BLACKSTONE TACTICAL OPPORTUNITIES ASSOCIATES III - NQ L.P., By: BTO DE GP - NQ L.L.C., GP, By: Blackstone Holdings II L.P., MM, By: Blackstone Holdings I/II GP L.L.C., GP, By: /s/ Tabea Hsi, Senior Managing Director 08/30/2021
    BTO DE GP - NQ L.L.C., By: Blackstone Holdings II L.P., its managing member, By: Blackstone Holdings I/II GP L.L.C., its general partner, By: /s/ Tabea Hsi, Name: Tabea Hsi, Title: Senior Managing Director 08/30/2021
    BLACKSTONE HOLDINGS II L.P., By: Blackstone Holdings I/II GP L.L.C., its general partner, By: /s/ Tabea Hsi, Name: Tabea Hsi, Title: Senior Managing Director 08/30/2021
    BLACKSTONE GLOBAL MASTER FUND ICAV, ACTING SOLELY ON BEHALF OF ITS SUB-FUND, BLACKSTONE AQUA MASTER SUB-FUND, By: Blackstone Alternative Solutions L.L.C., its investment manager, Name: /s/ Peter Koffler, Title: Authorized Person 08/30/2021
    BLACKSTONE ALTERNATIVE SOLUTIONS L.L.C, Name: /s/ Peter Koffler, Title: Authorized Person 08/30/2021
    BLACKSTONE HOLDINGS I L.P., By: Blackstone Holdings I/II GP, L.L.C., its general partner, Name: /s/ Tabea Hsi, Title: Senior Managing Director 08/30/2021
    BLACKSTONE HOLDINGS I/II GP L.L.C., By: /s/ Tabea Hsi, Name: Tabea Hsi, Title: Senior Managing Director 08/30/2021
    BLACKSTONE FAMILY TACTICAL OPPORTUNITIES INVESTMENT PARTNERSHIP III ESC L.P., By: BTO Side-by-Side GP L.L.C., its GP, By: Blackstone Holdings III L.P., its SM, By: Blackstone Holdings III GP Management L.L.C., its indirect GP, By: /s/ Tabea Hsi, SMD 08/30/2021
    BTO SIDE-BY-SIDE GP L.L.C., By: Blackstone Holdings III L.P., its sole member, By: Blackstone Holdings III GP L.P., its general partner, By: Blackstone Holdings III GP Management L.L.C., its general partner, By: /s/Tabea Hsi, Senior Managing Director 08/30/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CMLF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMLF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sherman Rachel E.

    4 - Sema4 Holdings Corp. (0001818331) (Issuer)

    10/19/21 7:31:01 PM ET
    $CMLF
    Business Services
    Finance

    SEC Form 4 filed by Turner Nat

    4 - Sema4 Holdings Corp. (0001818331) (Issuer)

    10/19/21 7:29:25 PM ET
    $CMLF
    Business Services
    Finance

    SEC Form 4 filed by Pellini Michael J

    4 - Sema4 Holdings Corp. (0001818331) (Issuer)

    10/19/21 7:27:37 PM ET
    $CMLF
    Business Services
    Finance

    $CMLF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

    37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

    3/14/22 4:05:00 PM ET
    $CMLF
    $SMFR
    Business Services
    Finance
    Retail: Computer Software & Peripheral Equipment
    Technology

    Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

    Sema4 Holdings Corp ("Sema4") to debut on Nasdaq as a publicly traded company dedicated to transforming healthcare by applying artificial intelligence and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human healthBusiness combination expected to result in ~$500 million in cash proceeds to Sema4 to accelerate organic and inorganic growthCombined company to trade on Nasdaq under ticker "SMFR" STAMFORD, Conn., July 22, 2021 (GLOBE NEWSWIRE) -- Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the completion of its business combination with CM Life

    7/22/21 9:15:41 AM ET
    $TWST
    $MGTA
    $CMLF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Business Services

    Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors

    Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of Directors. Mr. Ryan will begin serving on Sema4's Board of Directors upon his official appointment after Sema4 closes its previously announced business combination with CM Life Sciences (NASDAQ:CMLF), a special purpose acquisition company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005228/en/Jason Ryan (Photo: Business Wire) Mr. Ryan most recently served as Chief Operating and Financial Officer of Magenta Therapeutics (NA

    7/7/21 7:00:00 AM ET
    $TWST
    $CMLF
    $MGTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Business Services
    Finance

    $CMLF
    SEC Filings

    View All

    SEC Form 424B3 filed by CM Life Sciences, Inc.

    424B3 - Sema4 Holdings Corp. (0001818331) (Filer)

    10/14/21 9:58:15 PM ET
    $CMLF
    Business Services
    Finance

    CM Life Sciences, Inc. filed SEC Form 8-K: Leadership Update

    8-K - Sema4 Holdings Corp. (0001818331) (Filer)

    10/14/21 5:23:09 PM ET
    $CMLF
    Business Services
    Finance

    SEC Form S-8 filed by CM Life Sciences, Inc.

    S-8 - Sema4 Holdings Corp. (0001818331) (Filer)

    9/27/21 4:46:23 PM ET
    $CMLF
    Business Services
    Finance

    $CMLF
    Financials

    Live finance-specific insights

    View All

    Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

    37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

    3/14/22 4:05:00 PM ET
    $CMLF
    $SMFR
    Business Services
    Finance
    Retail: Computer Software & Peripheral Equipment
    Technology

    $CMLF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by CM Life Sciences, Inc.

    SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

    10/13/21 2:31:34 PM ET
    $CMLF
    Business Services
    Finance

    SEC Form SC 13D filed by CM Life Sciences, Inc.

    SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

    8/30/21 4:45:58 PM ET
    $CMLF
    Business Services
    Finance

    SEC Form SC 13D filed by CM Life Sciences, Inc.

    SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

    8/2/21 4:59:57 PM ET
    $CMLF
    Business Services
    Finance

    $CMLF
    Leadership Updates

    Live Leadership Updates

    View All

    Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer

    Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of Andrew Kasarskis, PhD, to the newly established role of Chief Data Officer (CDO). Dr. Kasarskis brings more than 20 years of leadership and broad experience in industry and academia that includes a strong focus on digital analytics and genomics and internationally recognized research in the life sciences. At Sema4, he will be responsible for establishing additional structures and processes to further optimize the company's health intelligence platform and orchestrating data use and data science to support research, development, and innov

    6/17/21 7:00:00 AM ET
    $CMLF
    Business Services
    Finance